Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST Long-Term Follow-Up of TX200-TR101
2024-512580-31-00Phase 3Authorised
- Sponsor
- Sangamo Therapeutics
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of TX200 in kidney allograft rejection, sponsored by Sangamo Therapeutics. Primary endpoints: Overall survival and Incidence and grade of serious adverse events. Planned start Jul 2024; status: authorised.
02
Drugs
TX200
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-512580-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512580-31-00.